Export 89 results:[ Author] Title Type Year
Filters: Type is Conference Proceedings [Clear All Filters]
The contribution of recent infections to HIV-1 transmission clusters in the UK. 18th International HIV Dynamics and Evolution Conference, 1-4 May 2011.. 2011.
The impact of resistance testing in ARV-naive patients: does it guide optimal therapy selection and improve long-term outcomes? British HIV Association 14th Annual Conference, 23-25 April 2008.. 2008.
Prevalence and predictors of protease inhibitor (PI) mutations in HIV-infected UK adults treated with ritonavir-boosted lopinavir as their first PI. 17th Annual Conference of the British HIV Association, 6-8 April 2011.. 2011.
Protease mutations emergining on darunavir in protease inhibitor-naive and experienced patients in the UK. International Congress of Drug Therapy in HIV Infection, November 2014.. 2014.
The Prevalence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK. 17th Conference on Retroviruses and Opportunistic Infections, February 2010.. 2010.
How common is the mutation E138K in the UK? 18th Annual Conference of the British HIV Association, 18-20 April 2012.. 2012.
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine within the UK CHIC cohort. 18th Annual Conference of the British HIV Association, 18-20 April 2012.. 2012.
Antiretroviral drug resistance in pregnant women living with HIV in England and Wales: Preliminary results from the matching of three national HIV surveillance databases. British HIV Association Conference (BHIVA) 2015.. 2015.
Detection of NNRTI resistance mutations after interrupting NNRTI-based regimens. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.. 2014.
Persistence of transmitted HIV drug resistance mutations. International Workshop on HIV & Hepatitis Virus Resistance and Curative Strategies, 5-9 June 2012. Antiviral Therapy 17 Suppl 1:A167.. 2012.
Trends in transmitted HIV drug resistance among non-B subtypes in the UK. Ninth International Congress on Drug Therapy in HIV Infection, 9-13 November 2008.. 2008.
Long-term probability of detecting HIV drug resistance in drug-naive patients starting currently recommended first-line combination ART. 15th Conference on Retroviruses and Opportunistic Infections, February 2008.. 2008.
National audit of baseline HIV resistance testing among newly-diagnosed adults. Third Joint Conference of BHIVA and BASHH, 1-14 April 2014.. 2014.
Rapid Increase in the Frequency of Wild Type HIV-1 Drug Resistance Reports among ART-experienced Patients: UK. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.. 2013.
Has a Limit to the Decline in Transmitted Drug Resistance Been Reached? Evidence from a Large Surveillance Study of UK-acquired Infections 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012.. 2012.
Time trends in HIV drug resistance in ART-experienced patients in the UK: impact of improved treatments and boosted protease inhibitors. 13th Annual Conference of the British HIV Association, 25-28 April 2007.. 2007.
Patterns of thymidine analogue mutations (TAMS) in samples sent for routine HIV drug resistance testing. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.. 2005.
Prevalence of reduced drug susceptibility in treatment-naive patients in the UK. 13th International Drug Resistance Workshop, 8-12 June 2004.. 2004.
Impact of HIV-1 subtype on genotypic resistance to protease inhibitors in the United Kingdom. 13th Conference on Retroviruses and Opportunistic Infections, 5-8 February 2006.. 2006.
Transmission dynamics of CRF50_A1D across most at risk communities in the UK. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.. 2012.